Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents
- PMID: 18559803
- PMCID: PMC2413314
- DOI: 10.1503/cmaj.071416
Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents
Abstract
Background: Measurement of bone mineral density is the most common method of diagnosing and assessing osteoporosis. We sought to estimate the average rate of change in bone mineral density as a function of age among Canadians aged 25-85, stratified by sex and use of antiresorptive agents.
Methods: We examined a longitudinal cohort of 9423 participants. We measured the bone mineral density in the lumbar spine, total hip and femoral neck at baseline in 1995-1997, and at 3-year (participants aged 40-60 years only) and 5-year follow-up visits. We used the measurements to compute individual rates of change.
Results: Bone loss in all 3 skeletal sites began among women at age 40-44. Bone loss was particularly rapid in the total hip and was greatest among women aged 50-54 who were transitioning from premenopause to postmenopause, with a change from baseline of -6.8% (95% confidence interval [CI] -7.5% to -4.9%) over 5 years. The rate of decline, particularly in the total hip, increased again among women older than 70 years. Bone loss in all 3 skeletal sites began at an earlier age (25-39) among men than among women. The rate of decline of bone density in the total hip was nearly constant among men 35 and older and then increased among men older than 65. Use of antiresorptive agents was associated with attenuated bone loss in both sexes among participants aged 50-79.
Interpretation: The period of accelerated loss of bone mineral density in the hip bones occurring among women and men older than 65 may be an important contributor to the increased incidence of hip fracture among patients in that age group. The extent of bone loss that we observed in both sexes indicates that, in the absence of additional risk factors or therapy, repeat testing of bone mineral density to diagnose osteoporosis could be delayed to every 5 years.
Figures
Comment in
-
Our approach to osteoporosis screening and treatment needs to change.CMAJ. 2008 Jun 17;178(13):1683-4. doi: 10.1503/cmaj.080672. CMAJ. 2008. PMID: 18559806 Free PMC article. Review. No abstract available.
References
-
- Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet 1993;341:72-5. - PubMed
-
- Schott AM, Cormier C, Hans D, et al. How hip and whole-body bone mineral density predict hip fracture in elderly women: the EPIDOS Prospective Study. Osteoporos Int 1998;8:247-54. - PubMed
-
- Kanis JA, Oden A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 2007;18:1033-46. - PubMed
-
- Cummings SR. How drugs decrease fracture risk: lessons from trials. J Musculoskelet Neuronal Interact 2002;2:198-200. - PubMed
-
- Melton LJ III, Atkinson EJ, O'Connor MK, et al. Bone density and fracture risk in men. J Bone Miner Res 1998;13:1915-23. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical